Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic stem cell transplantation for multiple myeloma: A two step approach to reduce toxicity involving high-dose melphalan and autologous stem cell transplant followed by PBSC [peripheral blood stem cell] allografting after low dose TBI [total body irradiation].

Next Previous
X
Search
Trial Profile

Allogeneic stem cell transplantation for multiple myeloma: A two step approach to reduce toxicity involving high-dose melphalan and autologous stem cell transplant followed by PBSC [peripheral blood stem cell] allografting after low dose TBI [total body irradiation].

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin; Cyclophosphamide; Melphalan; Mycophenolate mofetil; Paclitaxel
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Feb 2020 Biomarkers information updated
    • 07 Jun 2012 Planned end date changed from 1 Jun 2001 to 1 Dec 2002 as reported by ClinicalTrials.gov.
    • 29 Nov 2011 Additional location (Italy) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top